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Summary 
Administration of recombinant human interleukin 7 (rh)IL-7 to mice has been reported by our 
group to increase the exportation of myeloid progenitors (colony-forming unit [CFU]-c and CFU- 
granulocyte erythroid megakarocyte macrophage) from the bone marrow to peripheral organs 
(blood, spleen[s],  and liver). We now report that Ib7 also stimulates a sixfold increase in the 
number of more primitive CFU-S day 8 (CFU-Ss) and day 12 (CFU-Sn) in the peripheral blood 
leukocytes (PBL)  of mice treated with rhIL-7  for 7 d. Moreover, >90%  of lethally irradiated 
recipient mice that received PBL from rhIL,7-treated donor mice have survived for >6 mo whereas 
none of the recipient mice that received an equal number of PBL from diluent-treated donors 
survived. Flow cytometry analysis at 3 and 6 mo after transplantation revealed complete trilineage 
(T, B, and myelomonocytic cell) repopulation of bone marrow, thymus, and spleen by blood- 
borne stem/progenitor cells obtained from rhIL-7-treated donor mice. Thus,  IL-7 may prove 
valuable for mobilizing pluripotent stem cells with long-term repopulating activity from the 
bone marrow to the peripheral blood for the purpose of gene modification and/or autologous 
or allogeneic stem cell transplantation. 
utologous bone marrow (BM) transplantation has been 
used for support of high-dose chemotherapy in the treat- 
ment of various neoplastic diseases (1). Under steady-state 
conditions, the majority of primitive hematopoietic stem/pro- 
genitor cells reside in the bone marrow, and only a low number 
of these cells can be isolated from the peripheral blood. How- 
ever, additional peripheral blood progenitor cells (PBPC) and 
peripheral blood stem cells (PBSC) can be mobilized by treat- 
ment with myelosuppressive agents (2), or growth factors 
(3, 4). Recent studies have shown that PBPC and PBSC ex- 
hibit enhanced potential for engraftment as compared with 
BM transplantation  (4,  5). 
Recently our group demonstrated that administration of 
recombinant human (rh)IL-7 to mice mobilized myeloid pro- 
genitor cells from the BM to the spleen(s)  (6),  blood, and 
liver (7). Administration of rhIb7 to irradiated mice also in- 
creased the number ofmegakaryocytes and immature granu- 
locytes in the spleen in vivo (8).  In vitro rhIb7 enhanced 
CSF-induced  myeloid  colony  formation  from  primitive 
Lin-Sca-1 + murine BM progenitor cells, without effecting 
proliferation of committed Lin-Sca-1- myeloid progenitors 
(9).  These findings, in addition to the well-known effects 
of II:7 on lymphopoiesis (10), and the documented expres- 
sion of receptors for II:7 on myeloid cells (11), suggested that 
this cytokine also may play an important role in myelopoi- 
esis. The present studies were performed to determine whether 
rhlL-7 could mobilize PBSC with long-term reconstitution 
potential in lethally irradiated recipients. 
Materials and Methods 
Mice.  C57BL/6 (Ly 5.2) and their congenic C57BL/6-Ly 5.1 
mice (12) were obtained from the Animal Production Area of the 
National Cancer Institute-Frederick Cancer Research and Devel- 
opment Center, maintained  in a specific  pathogen-free  environment, 
and used between 8 and 10 wk of age. 
Reagents.  rhlb7 was purchased from PeproTech (Rocky Hill, 
NJ), and had asp act of 2  x  107 U/mg as measured by prolifera- 
tion ofa murine pre-B cell line (IxN/A6). The endotoxin level was 
<0.1 ng/ml. Lyophilized material was diluted in citrate buffer, pH 
6.0, to a concentration of 1 mg/ml. Mice received injections of 
rhlL-7 or diluent  HBSS without Ca 2+,  Mg  ;+  and phenol red 
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mouse serum [NMS]). 
Enrichment and Purification of Pe@heral Blood Leukocytes (PBL). 
Peripheral blood from C57BL/6-Ly 5.1 mice that had been treated 
with 5 #g of rhlL-7 or diluent twice daily for 7 d was collected 
by cardiac puncture and placed into EDTA-containing  tubes. Blood 
was pooled by group, layered over Lymphocyte Separation Media 
gradients of 1.077-1.080 g/ml (Organon Teknika, Durham, NC) 
and centrifuged at 800 g for 20 rain at 20~  Low density (LD) 
PBL from the interface were collected, washed, resuspended in plain 
HBSS, and then used for transplantation. 
Preparation of BM, Spleen Cells, and Thymocytes.  BM from both 
femurs and tibiae, spleen cells, and thymocytes were isolated from 
recipient mice (6, 7, 13) and resuspended  in HBSS plus 1% BSA 
(GIBCO/BRL, Bethesda, MD) for flow cytometric analysis (FCA). 
BM cells used for transplantation were resuspended  in cold HBSS. 
Transplantation.  C57BL/6 (Ly 5.2) recipient mice were exposed 
to  a  total  of  11.0 Gy  137Cesium irradiation  (dose  rate,  23.2 
cGy/min) delivered in two equal doses of 5.5 Gy given 3 h apart. 
The CFU-S assay was performed by the i.v. injection of 2  x  10  s 
LD PBL or BM cells from rhlb7-treated or HBSS-treated C57BL/ 
6-Ly 5.1 donor mice into irradiated recipients.  On days 8 and 12 
after transplantation,  the number of macroscopically  visible sur- 
face colonies (CFU-S) on fixed spleens was counted (14). Long- 
term survival and reconstitution studies were done by injecting var- 
ious numbers ofLD PBL or BM cells from rhlL-7-treated or HBSS- 
treated C57BL/6-Ly 5.1 donors intravenously into lethally irradi- 
ated C57BL/6  (Ly 5.2)  recipients. 
Surface Phenotype Analysis.  Hematopoietic reconstitution was 
determined by two- to three-color immunofluorescence labeling 
followed by FCA (6). Donor-derived (Ly 5.1 +) or host-derived (Ly 
5.2 +) cells were detected using the mAb clones A-20-1.7 or 104- 
2.1 (15), respectively, and developed with FITC-conjugated affanity- 
purified goat anti-mouse IgG2a (Fisher Scientific, Orangeburg, NY) 
or they were biotinylated and developed with Streptavidin-RED670 
(GIBCO BRL). B-lineage cells and granulocytes were detected using 
PE-conjugated  RA3-6B2  (B220)  or  PE-conjugated  RB6-8C5, 
respectively  (PharMingen,  San  Diego,  CA).  CD4 §  or  CD8 + 
T-lineage cells were detected using PE-conjugated GK 1.5 (L3T4) 
or biotin-conjugated 53-6.7 (Ly 2) developed with Streptavidin- 
RED670, respectively  (Becton Dickinson, San Jose, CA).  T  cells 
were detected using 500A2  (CD3) as previously described  (6). 
Statistical Analysis.  All statistical  evaluations  were performed 
using the computer software Instat ver. 2.02 or GraphPad Prism 
for Windows ver 1.0 (GraphPad Software, San Diego, CA). Statisti- 
cally significant differences based on absolute numbers were deter- 
mined by two-tailed, Student's t test (16). Results from survival 
experiments were analyzed by log-rank nonparametric test and ex- 
pressed as Kaplan-Meier  survival curves. 
Results and Discussion 
Administration  of 11_,7 Increases the Number of Circulating 
CFU-S. Lethally irradiated C57BL/6 (Ly 5.2) recipient mice 
were injected intravenously with 2  x  10 s LD PBL or BM 
cells from rhlL-7 (5/zg i.p./twice daily for 7 d) or HBSS- 
treated C57BL/6-Ly 5.1 donors. A statistically significant in- 
crease in the total number of CFU-Ss (p <0.001) and CFU- 
St2 (p <0.001) was observed after transfer of PBL from mice 
treated with rhlL-7 (day 8:700  +  87,  day 12:633  +  29) 
(Fig.  1 A) compared with PBL from donors injected with 
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Figure 1.  Effect  of systemic administration of rhlL-7 on progenitors  for 
CFU-S in peripheral  blood. Lethally  irradiated  recipient  mice (n = 6) were 
injected intravenously with  2  x  10  s  PBL obtained from rhIL-7 (5 
#g/twice daily for 7 d)- or HBSS-treated  (control) mice. After 8 and 12 d, 
mice were killed, and colonies  on the surface  of the spleens were counted. 
The results are presented as the mean number from three mice per group 
(at each time point)  -+  SD multiplied by the total number of cells ob- 
tained from donors and divided by 2  x  10  5 (the number of cells plated; 
A) or as the frequency  of CFU-S obtained per 2 x  10  s injected PBL (B). 
tion to its established ability to mobilize single-lineage CFU-c 
and multi-lineage CFU-granulocyte erythroid megakarocyte 
macrophage (GEMM) (7), IL7 potently mobilized primitive 
CFU-S from  the BM to the blood. 
PBL Isolated from rhlL 7-treated Donors Rescue Lethally Ir- 
radiated Mice.  To determine if rhlb7 could mobilize pluripo- 
tent stem cells, lethally irradiated C57BL/6 (Ly 5.2) recipients 
were transplanted with various numbers of PBL from C57BL/ 
6-Ly 5.1 donors that were pretreated with rhlL-7 (5 #g/twice 
daily). As shown in Fig.  2 A,  106 PBL obtained from rhlL- 
7-treated  donors rescued 90%  of the irradiated recipients, 
whereas the same number of PBL isolated from control donors 
produced no survivors. A  higher number of PBL (5  x  106 
and  1  x  107) transplanted from rhlL-7-treated donors res- 
cued 100% of the recipients, whereas these cell doses of PBL 
from control mice were much less efficient (5  x  106, 10% 
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Figure  2.  Survival of lethally irradiated recipients (Ly 5.2) transplanted 
with PBL isolated from donors  (Ly 5.1) treated  with rhlb7 or HBSS. 
Lethally irradiated  recipient  mice (n  =  10) were injected  intravenously 
with 106, 5  x  106 or 107 PBL from rhlL-7 (5 gg/twice daily for 7 d)- 
or HBSS-treated mice. The survival of mice was monitored for up to 200 d. 
The results are presented  as a Kaplan-Meier  survival curve. 
and 1  x  107, 70%).  These results demonstrated that PBL 
from rhIb7-treated mice were much more efficient in long- 
term rescue of irradiated recipients,  suggesting the mobiliza- 
tion  of  pluripotent  stem  cells  with  long-term  marrow 
repopulating activity. 
PBL fwm Mice 7~eated  with rMb 7 Contain Long-term Recon- 
stituting Stem Cells that Repopulate all Leukocyte Lineages in 
Lethally Irradiated Recipient Mice.  To determine if the rescue 
of lethally irradiated recipients by rhlL-7 mobilized PBL was 
associated with reconstitution by stem/progenitors cells trans- 
planted from donor mice, the percentage of donor (Ly 5.1 +) 
vs host (Ly 5.2 +) repopulation in BM, thymus, and spleen 
of surviving recipient mice was assessed by FCA at 3 (short- 
term repopulation) and 6 mo (long-term repopulation). The 
analysis of data at 3 mo revealed that 107 PBL from rhlL- 
7-treated donors reconstituted BM, thymus, and spleen cel- 
lularity to the same degree as did 106 BM cells from con- 
trol or rhlb7-treated donors (Table 1). Analysis of short-term 
host vs donor reconstitution in recipient mice transplanted 
with  107  PBL  from  rhlb7-treated  donors  (Fig.  3,  3 
Table  1.  Cellularity of Various Organs after Reconstitution with 






Cellularity ( x 106) 
Donor cells  3  mo  6  mo 
PBL (107 cells) - HBSS  8 -+ 3  17  _+  6 
PBL (10  + cells) - rhlL-7  28  _+  1  22  _+  3 
PBL (107 cells) - rhlL-7  23  _+  6  22  _+  4 
BM (1@ cells) - HBSS  16  +  5  20  +  6 
BM (106 cells) - rhlL-7  20  +  4  21  +  3 
PBL (107 cells) - HBSS  2  _+  2  23  _+  38 
PBL (10 6 cells) - rhlL-7  106  _+  17  24  _+  21 
PBL (107 cells) - rhlL-7  106  +  8  37  _+  24 
BM (106 ceils) - HBSS  80  -+  10  54  _+  9 
BM (106 cells) - rhlL-7  105  +  10  65  +  15 
PBL (107 cells) - HBSS  39  +  32  42  +  8 
PBL (10  + cells) - rhlL-7  81  -+  11  52  _+  16 
PBL (107 cells) - rhlL-7  85  -+  2  77  +  11 
BM (106 cells)- HBSS  74  _+  19  76  _+  8 
BM (10  + cells) - rhlL-7  59  -+ 6  65  +  2 
Lethally irradiated  recipient mice (n  =  6) were injected with 106 or 107 
i.v. PBL obtained from rhlL-7 (5/~g/twice daily for 7 d)-treated mice, 
107 PBL from HBSS-treated  mice (control)  or 106 BM cells obtained  af- 
ter either treatment.  At 3 and 6 mo after transplantation,  three mice from 
each group were euthanized  and tibias, femurs,  spleens, and thymi were 
collected individually from each group. BM cells, thymocytes, and spleno- 
cytes were isolated as described in Materials and Methods and counted. 
The results are presented  as the mean of three mice per group  _+  SD. 
MONTHS)  demonstrated that the majority of the cells in 
various organs were of donor origin (the percentage of donor 
Ly 5.1 + cells ranged from 89  to >99).  These percentages 
were significantly (p <0.001) greater than those obtained from 
reconstitution by 107 PBL from control mice which showed 
only 8% donor reconstitution of the bone marrow and 5% 
donor reconstitution of the thymus in recipient mice. After 
3 mo, reconstitution of the spleen with 107 PBL was some- 
what better (27 _+ 8%), but was still significantly  lower than 
the reconstitution achieved  by  106  ~  <0.05)  or  107  (p  < 
0.001) PBL from rhlb7-treated mice. Thus, the repopula- 
tion that occurred in the group that received 107 PBL from 
control donors was largely of recipient origin by 3 mo. The 
transfer of 106 PBL from rhlL-7-treated donors also resulted 
in better mean levels of percent donor repopulation than did 
107 transferred normal PBL, but the variability was higher 
among the responding mice (Fig.  3, 3 MONTHS). 
Because the 3-mo survival assay is considered to be a good 
measurement for only short-term repopulating stem cells (17), 
repopulation was also  analyzed at  6 mo, which measures 
repopulation by totipotential stem cells. As shown in Table 
1,  all of the recipients  had considerable  repopulation by 6 
mo; however the reconstitution of the spleen by 107 PBL 
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Figure  3.  Percentage  of  donor 
cells (Ly 5.1 +) repopulating various 
organs of lethally irradiated recip- 
ient  (Ly  5.2 +)  mice  transplanted 
with PBL and BM cells from rhIL-7- 
or HBSS-treated donors. Lethally ir- 
radiated recipient mice (n =  6) were 
injected intravenously with  10  6 or 
10  7 PBL  obtained from rhlL-7 (5 
/~g/twice  daily  for  7  d)-treated 
mice,  10 7  of  PBL  from  HBSS- 
treated mice (control), or with 10  6 
BM cells obtained from either treat- 
ment.  At 3  and 6  mo after trans- 
plantation,  three  mice from  each 
group  were  killed,  and  tibiae, 
femurs, spleen, and thymi were col- 
lected individually from each group. 
BM cells,  thymocytes, and spleno- 
cytes  were  isolated  and  counted. 
Cells were labeled with anti-Ly 5.1 
or anti-Ly 5.2 to determine whether 
they were of donor or host origin 
as described in  the Materials  and 
Methods.  The inset table demon- 
strates multiple-lineage reconstitu- 
tion determined by the percentage 
of  total  RB6-8C5+  (8C5+), 
CD3+,  B220 +, CD4+,  or CD8 § 
cells that were of donor origin. The 
results are presented as the mean of 
three mice per group  _+  SD. 
from control mice was significantly lower (p <0.05)  when 
compared with PBL (107) from the rhlL-7-treated mice and 
BM from normal or rhlL-7-treated mice. The percentages 
of  donor ceils in surviving mice at 6 mo were similar to those 
noted at 3 mo (Fig. 3). The efficiency  of overall donor-origin 
cell repopulation  in some organs was less in mice that re- 
ceived 107 PBL from control mice versus those that received 
107 PBL from rhlL-7-treated donors (BM, 4  +  1% vs 92 _+ 
4%; thymus, 5  +- 6% vs 98  +  1%; and spleen, 18  +  6% 
vs 94  _+  1%).  In fact,  the effidency of donor-origin cell 
repopulation by 107 PBL from rhlb7-treated donors was as 
good as that achieved by 10  + normal BM cells. Mice trans- 
planted with 106 PBL from rhlb7-treated donors at 6 mo 
exhibited higher variability in terms of the percentage of  donor 
cells for various organs (BM, 33 _+ 51%; thymus, 41 _+ 51%; 
spleen, 51  +  36%), but those mean percentages tended to 
be much higher than those attained by 107 PBL from normal 
donors. 
These results show that administration of rhIL-7 can mobi- 
lize progenitor and stem ceils required for both short- and 
long-term repopulation. Successful  repopulation with donor 
ceils was dependent on the number of  PBL transplanted, with 
a dose of 10  + from rhlL-7-treated donors being borderline 
for complete survival and repopulation of irradiated recipients, 
whereas  107 PBL or 106 BM cells were able to efficiently 
repopulate recipient mice. Interestingly,  107 PBL from con- 
trol donors also were able to rescue some mice for 6 too, how- 
ever ultimately repopulation was largely of host origin. Thus, 
normal peripheral blood contains adequate numbers of short- 
term repopulating ceils (STRC) (18) to allow survival of ir- 
radiated mice; however, there are few long-term repopulating 
cells  (LTRC),  which  predominantly contribute  to  both 
3- and 6-mo survival. The frequency of STRCs in normal 
PBL must be low since 106 PBL from control mice failed 
to rescue any recipients. In fact, as shown in Fig. 1 (B), there 
were only 4  _  1 CFU-Ss and 4  _+  2 CFU-St2 per 2  x  105 
cells detected in the blood of control mice, whereas the rhlL- 
7-treated mice showed a significant increase (p <0.001) in 
the frequency of these progenitors (e.g., 14  _  2 CFU-Ss and 
13  _  1 CFU-S~). This increase might contribute to the ob- 
servation that 10-fold fewer PBL from IL-7-treated mice were 
able to fully rescue mice compared with PBL from normal 
mice. Although 106 PBL from rhlb7-treated donors and 107 
PBL from control mice were able to rescue the lethally ir- 
radiated recipients, only PBL from mice treated with rhlb7 
could successfully repopulate  various  organs  with donor- 
derived cells, further suggesting that PBL from control mice 
contain STRCs supporting early BM recovery, followed by 
repopulation  with host-originated  LTRCs that survived ir- 
radiation. In contrast, PBL from rhlL-7-treated donors pro- 
vide both STRCs for initial recovery and LT1LCs that sustain 
long-term hematopoiesis. This is further emphasized by the 
data shown in Fig. 3, inset table,  where complete trilineage 
(T and B cell, and myelomonocytic cell) reconstitution is 
demonstrated in various organs. A similar trend also was ob- 
served by 3 mo (data not shown). 
Interestingly, BM cells from rhlL-7-treated  mice were al- 
most equal to BM cells from control mice in repopulating 
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mature progenitors were reduced in BM from mice treated 
with rhlL-7 (CFU-C and CFU-GEMM) (6, 7), suggesting 
that the ability of such BM to repopulate lethally irradiated 
mice might  also be diminished.  The data presented herein 
suggest that  at least some threshold  number of short- and 
long-term repopulating cells are retained in BM from rhlL- 
7-treated mice. This is in agreement with previous data that 
various progenitors detected by different colony-forming assays 
do not always equate to an ability to reconstitute short- and 
long-term  hematopoiesis in irradiated  mice (19). 
Several  hematopoietic  growth  factors (HGF) have been 
studied as mobilizing  agents,  alone or in combination,  in 
preclinical studies or clinical  trials (e.g., G-CSF, GM-CSF, 
IL-3/Epo, IL-1, stem cell factor [SCF], IL-11) (4, 20). Some 
HGFs have their activity restricted to myelopoiesis whereas 
others stimulate lymphopoiesis and myelopoiesis (21). To date, 
ID7 had been reported to primarily stimulate lymphopoiesis 
(13, 22), with a pronounced increase in the number of ma- 
ture T  lymphocytes, particularly CD8 + T  cells,  as well as 
T cell-mediated responses (13). Additionally, we found that 
II.-7 also influenced early myeloid progenitors (7). In this re- 
gard,  IL-7 has been shown to synergize with GM-CSF and 
SCF to enhance in vitro myeloid colony formation of Lin- 
Sca-1 + routine BM progenitor  cells (9). 
In summary,  rhlb7  has novel functions in vivo because 
of its ability to mobilize myeloid stem cells/progenitors from 
the BM to periphery, its ability to accelerate regeneration of 
donor  B  and  T  lineages  after  transfer  to  irradiated  hosts 
(Boerman, O. C., T. A. Gregorio, K. Grzegorzewski, C. R. 
Faltynek, R. L. Wiltrout, and K. L. Komschlies, manuscript 
submitted for publication),  and documented potent effects 
on lymphocyte proliferation  and T  cell function  (13).  The 
mechanism of action for the stem cell mobilizing effects of 
rhlb7, as well as those for G-CSF and SCF, remains unknown 
and may be at least partially indirect  through induction of 
other mobilizing cytokines (23) or through inhibition of nega- 
tive regulators of hematopoiesis (24). A comparison of the 
mobilizing ability of rhlL-7 with other cytokines and its ability 
to synergize with other stem cell mobilizers is in progress. 
Ultimately, rhIL-7 may prove useful for increasing the effidency 
of stem cell mobilization into the peripheral blood for gene 
transfer studies, and for autologous or allogeneic stem cell 
transplants. 
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